Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

– Acquisition adds Zavante’s CONTEPO ™ , potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio – – Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 – – Ted Schroeder

READ FULL TEXT

Leave a Reply

Your email address will not be published.